



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

May 11, 2023

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

Scrip code: 500672

Dear Sir/ Madam,

Sub.: Intimation of Newspaper Advertisement by Novartis India Limited ('the Company') regarding the Audited Financial Results of the Company for the quarter and year ended March 31, 2023

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as per the subject matter quoted above, please find enclosed herewith the copies of newspaper advertisements published in "Financial Express" and "Navshakti" on May 11, 2023.

This is for your information and records.

Thanking You.

Yours Sincerely,

For Novartis India Limited



Nikhil Malpani
Company Secretary and Compliance Officer

Encl.: as above

MINER WORKING WITH PROFIT MOTIVE, SC TOLD

CIL can't take refuge under 1973 Act: CCI

Legislation does not relate to trade of coal, says regulator

MANISH GUPTA
New Delhi, May 10



THE COAL MINES (Nationalisation) Act, 1973, is an expropriatory legislation and does not relate to trade and commerce of coal, and thus does not protect Coal India (CIL) from the competition laws, the counsel for the Competition Commission of India (CCI) said in the Supreme Court on Wednesday.

Addressing the bench of Justices KM Joseph, BV Nagarathna and Ahsanuddin Amanullah, the CCI maintained that the CIL is working with a profit motive and is not serving any "common good" when it has been "unilaterally fixing the terms of Fuel Supply Agreements (FSA) with different power companies."

"Section 54 of the Competition Act, 2002, provides for exemptions and the government has exercised its power in two cases, but has not exempted Coal India from application of the competition law," the CCI counsel noted.

The Competition Act, 2002, which replaced the Monopolies

and Restrictive Trade Practices (MRTP) Act, 1969, reversed the ruling on exemptions from not applicable to all undertakings owned by the government or corporation to applicable to all unless exempted by the government through notification. It may be noted that CCI had imposed a penalty of ₹1,773 crore in 2013 on CIL for abusing its dominant position and imposing unfair conditions in FSAs with the power companies for supply of non-coking coal. After the intervention of Competition Appellate Tribunal, the penalty was cut to ₹591 crore.

CIL then appealed in the Supreme Court arguing that all its coal mines as per the Coal Mines (Nationalisation) Act, 1973, are fully outside the purview of the competition law. It also stated that the coal market was influenced by factors beyond its control like gov-

ernment policies and environmental regulations.

"More than the CIL, the power companies are serving common good as tariff for common people is determined by the electricity commission," the advocate said, adding that coal is no more an essential commodity and that CIL does not do retail sale of coal unlike earlier years when it had depots. He said that Coal India has been working mainly for profits as it never supplies coal without first asking for the money. It increased its profits four times after the introduction of New Coal Distribution Policy, as it allowed CIL to unilaterally decide the price in FSAs, he said.

The policy states: "100% of the quantity as per the normative requirement of the consumers would be considered for supply of coal, through FSA by CIL at fixed prices to be declared/ notified by CIL."

The three-judge bench directed the respondent to complete its submission by Thursday and said that the court needs to ascertain the definition of enterprise, a dominant enterprise and whether CIL abused its dominant position. Justice Joseph observed that the competition law is important for both private and public enterprises as private players calling the shots can be detrimental to the country.

Connectivity projects must respect sovereignty: India, EU

INDIA AND THE European Union (EU) took stock of their negotiations for a free trade agreement and an

investment protection pact even as they asserted that connectivity projects must respect sovereignty and ter-

ritorial integrity. The two sides deliberated on these issues at their fourth strategic partnership

review meeting that was held in Delhi on Monday. India and the EU also underscored the need for

"comprehensive, just, and lasting" peace in Ukraine, said a joint statement released on Wednesday. PTI

HATSUN AGRO PRODUCT LIMITED						
CIN: L15499TN1986PLC012747						
Regd. office: No.41 (49), Janakiram Colony Main Road, Janakiram Colony, Arumbakkam, Chennai 600 106. Tel: 044 - 4365 9999; Fax: 044 - 4365 9998 Email: secretarial@hap.in Website: www.hap.in						
AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2023						
(₹ in Lakhs except EPS)						
S.No.	Particulars	Quarter ended March 31, 2023 Unaudited	Quarter ended December 31, 2022 Unaudited	Quarter ended March 31, 2022 Unaudited	Year ended March 31, 2023 Audited	Year ended March 31, 2022 Audited
1.	Total Income from operations	1,79,108.63	1,69,563.42	1,62,731.19	7,25,752.86	6,38,017.51
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	3,288.36	6,317.54	4,997.53	22,455.83	27,538.14
3.	Net Profit/(Loss) for the period before Tax (after Exceptional and/ or Extraordinary Items)	3,288.36	6,317.54	4,997.53	22,455.83	27,538.14
4.	Net Profit/(Loss) for the period after Tax (after Exceptional and/ or Extraordinary Items)	2,498.59	4,643.62	2,964.06	16,585.62	21,790.94
5.	Total Comprehensive Income for the period	2,358.14	4,643.62	2,806.35	16,445.17	21,659.30
6.	Paid-up Equity share capital (Face value of Re. 1/- per share)	2,227.87	2,156.02	2,156.02	2,227.87	2,156.02
7.	Reserves (excluding Revaluation Reserve as shown in the audited Balance Sheet of previous year)	-	-	-	1,41,839.77	1,08,720.49
8.	Earnings per share (of Re.1/- each) (Not annualised):					
a.	Basic	1.12	2.12	1.34	7.54	9.88
b.	Diluted	1.12	2.12	1.34	7.54	9.88

Note:
1. The above is an extract of the detailed format of Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the website of the Stock Exchange(s) (www.bseindia.com and www.nseindia.com) and the Listed entity (www.hap.in)
2. The above Audited Financial Results prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 have been reviewed by the Audit Committee and approved by the Board of Directors at their Meeting held on May 9, 2023.

For Hatsun Agro Product Limited
Sd/-
C. Sathyan, Managing Director
DIN: 00012439

Place: Chennai
Date: May 09, 2023

Centre invites bids from pvt investors for morphine unit

SURABHI
New Delhi, May 10

THE CENTRE PLANS to set up a new production unit for manufacturing concentrated poppy straw (CPS) for extraction of semi-refined morphine. The production unit will be set up near Neemuch in Madhya Pradesh on a public-private partnership basis with an investment of ₹165 crore.

Accordingly, the finance ministry has invited bids for the new production unit with a minimum capacity to process 10,000 million tonne of poppy husk per annum. It would use the CPS technology to process the poppy husk and further extract semi-refined morphine from it.

According to sources, the private player would only produce the crude form of alkaloids and the final alkaloids will be processed by Government Opium and Alkaloid Factories (GOAM) for sale to domestic pharma companies. If there is a surplus, a decision can be taken to export it as well, they added.

The CPS method remains relatively new to India and this would be the second such facility being set up in the country, although its size and



A production unit will be set up near Neemuch in Madhya Pradesh on a public-private partnership basis, with an investment of ₹165 crore

scale would be much larger.

The government had last year signed a five-year contract for job work with Bajaj Healthcare, which has a factory at Savli in the Vadodara district of Gujarat. The company has the mandate to process 500 MT of unalanced poppy straw to manufacture CPS and extract alkaloids as well as to process 100 MT of opium gum per year to extract alkaloids.

India is one of the few countries internationally permitted to cultivate opium poppy for export and had a few years ago decided that the CPS method would be used. The Opium Policy 2021-22 had allowed licences to culti-

vators for production of unalanced poppy straw that would be used in manufacturing of alkaloids using the CPS technology.

All other opium-growing countries follow this process and demand for Indian opium has been declining in recent years. It is expected that with the use of CPS technology India will regain its market place in the segment. It is also less labour-intensive and has higher productivity. According to the bid document, the production facility would be set up 75 km near Neemuch and the concession period would be for a 20-year period including three years of construction.

The private player would create a production block, adequate storage space for poppy husk and finished products.

It would also create facilities using CPS technology to process husk and further extraction of semi refined morphine, alkaloids or crude form of alkaloids as instructed. They would also ensure that the extracted materials meet the international quality norms, standards and certification as followed in US, the UK, Europe and Australia.

Nazara Technologies Limited											
CIN: L72900MH1999PLC122970											
Regd. Office: 51-54, Maker Chambers 3, Nariman Point Mumbai - 400021 Tel.: +91-22-40330800 Fax: +91-22-22810606 Email: info@nazara.com Website: www.nazara.com											
EXTRACT FROM THE AUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS OF NAZARA TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023											
(₹ in Millions)											
Sr. No.	Particulars	CONSOLIDATED			STANDALONE						
		Quarter Ended		Year to date	Quarter Ended		Year to date				
		31.03.2023 Audited	31.12.2022 Unaudited	31.03.2022 Audited	31.03.2023 Audited	31.12.2022 Unaudited	31.03.2022 Audited				
1	Total Income from Operations	2,975	3,263	1,847	11,405	6,458	114	127	86	497	330
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items*)	165	261	108	888	699	(113)	24	(159)	(212)	(346)
3	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items*)	94	201	49	614	507	(120)	22	(187)	(240)	(338)
4	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	106	237	78	801	577	(121)	23	(188)	(242)	(340)
5	Equity Share Capital (Face Value of ₹ 4/- each)	265	264	130	265	130	265	264	130	265	130
6	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	10,784	10,283	-	-	-	8,894	8,857
7	Earnings Per Share (of ₹ 4/- each) (for continuing and discontinued operations)										
	Basic (in ₹):	0.01	2.49	0.34	5.98	4.55	(1.83)	0.35	(2.88)	(3.67)	(5.41)
	Diluted (in ₹):	0.01	2.47	0.34	5.97	4.55	(1.83)	0.35	(2.88)	(3.67)	(5.41)

* Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules/AS Rules, whichever is applicable.

Notes:
1. The above is an extract of the detailed format of Quarterly and Year ended financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the Stock Exchange websites: www.bseindia.com, www.nseindia.com and on the Company's website: www.nazara.com.
2. The detailed financials results and this extract were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on May 9, 2023.

By Order of the Board
For Nazara Technologies Limited
Sd/-
Nitish Mittersain
Joint Managing Director and Chief Executive Officer
DIN: 02347434

Place: Mumbai
Date: May 9, 2023

THE INVESTMENT TRUST OF INDIA LIMITED

Regd. Office: ITI House, 36 Dr.R.K. Shirodkar Road, Prest, Mumbai - 400 012
Tel.: +91-22-4027 3600; Fax: +91-22-40273700; Email: info@itiorg.com; Website: www.itiorg.com
CIN: L65910MH1991PLC062067



STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023						
(₹ in lakhs)						
Sr. no.	Particulars	Quarter ended		Year ended		
		31.03.2023 Audited	31.12.2022 Unaudited	31.03.2022 Audited	31.03.2023 Audited	31.03.2022 Audited
1	Total Income	8,419.66	7,135.84	8,231.52	32,423.11	33,934.06
2	Net profit/(Loss) for the period (before tax, exceptional items and share of profit of associates)	1,368.15	78.82	(123.64)	1,764.62	814.24
3	Net profit/(Loss) for the period before tax (after exceptional items and share of profit of associates)	1,575.23	178.65	18.34	2,182.26	1,197.01
4	Net Profit/(Loss) for the period (after tax, exceptional items, non-controlling interest and share of profit of associates)	1,316.29	22.98	(73.33)	1,157.37	145.09
5	Total Comprehensive Income/(Loss) for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	1,269.34	33.38	(27.97)	1,144.16	190.55
6	Paid up Equity Share Capital (Face value ₹ 10 per share)	5,224.22	5,224.22	5,152.03	5,224.22	5,152.03
7	Other Equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	58,415.88	54,930.88
8	Earnings per share before and after extraordinary items (face value of ₹ 10 each)					
	Basic (₹)	2.50	0.05	(1.55)	2.21	0.31
	Diluted (₹)	2.50	0.05	(1.55)	2.21	0.30

Notes:
1. The above results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of The Investment Trust of India Limited ("the Company") at its meeting held on May 9, 2023. The Statutory Auditor of the Company has carried out an Independent Auditors' Review of Interim Consolidated Financial Results. The statutory auditors have issued audit report with unmodified opinion on the above results.
2. These results have been prepared in accordance with the Indian Accounting Standards (referred to as "Ind AS") Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time.
3. The above is an extract of the detailed audited quarter and year ended March 31, 2023 Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Financial Results of the quarter and year ended March 31, 2023 are available on the BSE website at www.bseindia.com, NSE website at www.nseindia.com, and the Company's website at www.itiorg.com
4. Standalone information:

Particulars	Quarter ended		Year ended	
	31.03.2023 Audited	31.12.2022 Unaudited	31.03.2022 Audited	31.03.2023 Audited
Total Income	2,078.46	2,505.53	2,864.53	11,072.45
Profit/(Loss) before tax	441.55	67.71	(277.27)	695.13
Profit/(Loss) after tax	427.89	70.44	(252.94)	692.50

For and on behalf of the Board
The Investment Trust of India Limited
Chintan V. Valia
Non Executive Director and Chairman
DIN: 05333936

Mumbai, May 09, 2023
Please visit us at www.itiorg.com

NOVARTIS INDIA LIMITED				
Registered Office: Inspire BKC, Part of 601 & 701, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Maharashtra, India. Tel.: +91 22 50243000; Fax: +91 22 50243010; Email: india.investors@novartis.com; Website: www.novartis.in; CIN: L24200MH1947PLC006104				
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2023				
(₹ in Million)				
Particulars	3 months ended 31.03.2023	3 months ended 31.03.2022	Year ended 31.03.2023	Year ended 31.03.2022
	(Audited)	(Unaudited)	(Audited)	(Audited)
Total Income	925.0	1,126.3	4,368.5	4,330.6
Net Profit for the period before exceptional item and tax	233.1	182.9	1,153.8	458.2
Exceptional items	-	496.4	-	496.4
Net Profit/(Loss) for the period after tax	250.2	(233.7)	1,033.6	(37.2)
Total Comprehensive income/(loss) for the period (comprising profit/(loss) for the period after tax and other comprehensive income after tax)	281.3	(212.9)	1,064.7	44.7
Equity Share Capital (of ₹ 5 each, fully paid)	123.4	123.4	123.4	123.4
Other Equity	-	-	7,633.2	6,793.6
Earnings Per Share (of ₹ 5 each) (*not annualised)	10.13*	(9.47)*	41.86	(1.51)
Basic and Diluted (₹)				

Note:
1. The above is an extract of the detailed format of Financial Results for the quarter and year ended 31st March, 2023 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results for the quarter and year ended 31st March 2023 are available on the stock exchange website, www.bseindia.com and on the Company's website, www.novartis.in
2. Total income for the year ended 31 March, 2023 and 31 March, 2022 includes interest on income tax refund aggregating to ₹ 267.5 millions and ₹ 46.3 millions respectively and for the quarters ended 31 March, 2023 and 31 March, 2022 ₹ 50.5 millions and ₹ 46.3 millions respectively. Total income for the quarter and year ended 31 March, 2023 includes profit on disposal of assets held for sale ₹ 26.5 million.
3. The Company had entered into an exclusive sales and distribution agreement with Dr. Reddy's Laboratories Limited of its Established Medicine Brand. This strategic business decision has led to an exceptional expense of ₹ 496.4 millions (net of re-evaluation of retirement obligations) for the quarter and the year ended 31 March, 2022 towards its erstwhile associates under employee separation scheme.

By Order of the Board
Sanjay Murdeshwar
Vice Chairman and Managing Director
DIN: 01481811

Place : Mumbai
Date : 10 May, 2023

